Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Demographic details of the two different patient cohorts used for genotyping and gene expression studies.

From: Adenosine receptor expression in rheumatoid synovium: a basis for methotrexate action

  225 patients for ADORA polymorphisms 20 patients for synovial gene expression
Age (years) 59.5 (18 to 84) 66.4 (48 to 80)
% Female 72% 90%
Disease duration (years) 10.4 (0.17 to 57) 21.1 (3.7 to 47)
Nodules 56 (24.9%) 12 (60%)
Erosions 139 (61.8%) 19 (95%)
RF +positive 178 (79.1%) 17 (85%)
CCP positive 165/214 (77.1%) 11/15 (73.3%)
Receiving MTX 225 (100%) 11 (55%)
MTX dose (mean) (mg/wk) 15.8 (5 to 25) 16.4 (7.5 to 20)
ESR 16.6 (2 to 96) 41.4 (14 to 74) (n = 10)
CRP 10.9 (0 to 150) 18.9 (3 to 79) (n = 17)
Anti-TNF therapy 0 3 (15%)
Prednisone 71 (31.6%) 6 (30%)
  1. ADOR, adenosine receptor; CCP, cyclic citrullinated peptide; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; MTX, methotrexate; TNF, tumor necrosis factor; RF, rheumatoid factor.